GlaxoSmithKline’s Arzerra Gets Better CLL Label, But Now Faces Competition With Gazyva

GlaxoSmithKline exec Klaus Edvardsen says the new label should give drug a boost, as previous indication was very restrictive. Approved in 2009, Arzerra had just £75 million in 2013 worldwide sales.